

**BOOK BY OCTOBER 11
TO SAVE UP TO
\$800**

February 25-27, 2020 | Boston, USA

www.as-immunetolerance.com



^{3rd}Antigen-Specific Immune Tolerance Drug Development

Translating Emerging Antigen Specific Immune Tolerance Approaches for Therapeutic Applications

31 Expert Speakers Including:



Matthias von Herrath
Vice President
Novo Nordisk



David Alleva
Executive Director
Akston Biosciences



Martin Roland
Head - Department of
Neuroimmunology & Multiple
Sclerosis Research
University Hospital Zurich



Emilio Flano
Director & Head of
Immunology Discovery
Merck & Co



Jack Ragheb
Senior Medical Fellow for
Immunology in Global
Patient Safety
Eli Lilly & Co.



Curtis Ruegg
President & Chief
Executive Officer
**Parvus Therapeutics,
Inc.**



Arpita Maiti
Executive Director &
Global Head
Pfizer



Lawrence Steinman
Professor of Neurology,
Neurological Sciences &
Pediatrics
Stanford University

Innovation Partner:



Event Partner:



Antigen Specific Immune Tolerance Summit 2020 (ASIT)

Optimize discovery pathways and the validation of novel targets, enhance your clinical trial success rate by improving the efficacy of current tolerance delivery systems and explore the fundamental mechanisms that define successful and unsuccessful clinical trials.

The **3rd Antigen Specific Immune Tolerance Summit (ASIT)** is committed to delivering industry leading content to facilitate the discussion, reflection and optimization of current clinical practices in order to overcome the hurdles impeding progress of drug development within the field.

Join this meeting to **optimize novel target discovery pathways**, explore cross learning opportunities from parallel fields tackling tolerance induction and **tackle the complexity of autoimmune** disorders in order to **facilitate a more precise and antigen specific approach** to drug development.

Share the floor with over 80 of your peers from pharma, biotech and academia. Join the discussion towards leading industry discussions surrounding optimal immune tolerance induction and current tolerance delivery practices in order to accelerate the translation of safe and effective immune tolerance therapies into the clinic.

See what our previous speakers think

Progress in immune tolerance therapies transcends individual diseases or single therapeutic platforms. We can share ideas and learn from each other in order to move forward with optimized clinical strategies and trials

Gerald (Jerry) Nepom, Director, Immune Tolerance Network

The meeting is an excellent event for networking but also an opinion generator for developing these novel therapeutics clinically in the exciting field of antigen-specific immune tolerance induction

Timm Jessen, Chief Executive Officer, Topas Therapeutics

Attend this meeting to:




Explore cross learning opportunities to benchmark your progress of drug development for antigen specific immunotherapies against parallel fields also tackling immune tolerance and **accelerate translation into the clinic**



Enhance your clinical trial success rate by examining and evaluating current tolerance delivery practices and explore novel advances in employing tolerance inducing adjuvants



Optimize and enhance your discovery pathways and validation processes of novel targets for antigen specific immune tolerance therapeutics



Discover clinical opportunities to employ novel therapeutics in combination with antigen specific immunotherapies and **drive progression of drug development towards the clinic**



Join the debate and **work towards defining tolerance induction** and the parameters by which tolerance itself can be measured



Review some of the first clinical trial readouts for antigen specific immune tolerance therapeutics and **explore the fundamental mechanisms** that lie behind successful and unsuccessful clinical trial design and delivery

Your 31 Expert Speakers



Andreas Lutterotti
Head of Experimental
Therapies Research
**University Hospital
Zurich**



Stephen Miller
Co-Founder of **Cour
Pharmaceuticals**;
Professor of
Microbiology-
Immunology
**Northwestern
University Medical
School**



Aaron Michels
Associate Professor of
Pediatrics Medicine, &
Immunology, Barbara
Davis Center for
Diabetes, **University
of Colorado**; Chief
Scientific Officer
IM Therapeutics



**Shahrokh
Shabahang**
Chief Innovation
Officer
AdiTx Therapeutics



Kei Kishimoto
Chief Scientific
Officer
Selecta Biosciences



David Alleva
Executive Director
Akston Biosciences



Giles Benichou
Associate Professor
of Surgery, **Harvard
Medical School**,
Senior Immunologist
**Massachusetts
General Hospital**



**Matthias von
Herrath**
Vice President
Novo Nordisk



Emilio Flano
Director & Head
of Immunology
Discovery
Merck & Co



Martin Roland
Head - Department
of Neuroimmunology
& Multiple Sclerosis
Research
**University Hospital
Zurich**



Dolly Tyan
Professor; Emerita of
Pathology
**Stanford University
School of Medicine**



Lawrence Steinman
Professor of
Neurology,
Neurological Sciences
& Pediatrics
Stanford University



Anne De Groot
Founder, Chief
Executive Officer
& Chief Scientific
Officer
Epivax



Ben Williams
Program Officer for
the Type 1 Diabetes
(T1D) Program
**Helmsley Charitable
Trust**



Giorgio Raimondi
Associate
Scientific Director
for Transplant
Immunology
**John Hopkins
School of Medicine**



Cory Berkland
Distinguished
Professor, School
of Pharmacy
Pharmaceutical
Chemistry
University of Kansas



Todd Zion
President & Chief
Executive Officer
Akston Biosciences



Garth Ringheim
Director Immunology
Therapeutic Area
Clarivate Analysis

Your 31 Expert Speakers



Curtis Ruegg
President & Chief
Executive Officer
Parvus
Therapeutics, Inc.



Jack Ragheb
Senior Medical Fellow
for Immunology in
Global Patient Safety
Eli Lilly & Co.



Arpita Maiti
Executive Director &
Global Head
Pfizer



Kristina M. Harris
Director, Biomarker &
Discovery Research
Immune Tolerance
Network



Joshua Sestak
President & Chief
Executive Officer,
Founder
Orion BioScience



Monali Manohar
Life Science Research
Scientist
Stanford University
School of Medicine



Colin Dayan
Professor of
Clinical Diabetes &
Metabolism
Cardiff University
School of Medicine



David Wraith
Director of the
Institute of
Immunology &
Immunotherapy
University of
Birmingham



Stephan Kontos
Founder & Chief
Scientific Officer
Anokion



Simi Ahmed
Director of Research
& Lead of the
Immune Therapies
Program
JDRF



Waldo Concepcion
Professor of Surgery
(Abdominal
Transplantation)
& of Pediatrics
(Nephrology)
Stanford University
Medical Center



Amy Rosenberg
Director -
Therapeutic Proteins
& CDER
FDA



Kurt Griffin
Associate Professor
University of South
Dakota Sanford
School of Medicine

■ This meeting will provide opportunities to network with key scientists, hear about the latest developments and state-of-the art science in the field of immune tolerance ■
Antoon Van Oosterhout, VP & Head Allergic Inflammation Discovery Performance Unit, GSK

Pre-Conference Workshop Day Tuesday February 25, 2020

Workshop A

9:00am – 12:00pm

Optimizing Novel Target Discovery

Bringing together experts from the autoimmune field, this workshop will discuss the common challenges facing target discovery and validation.

Whilst there are now multiple varying tolerance platforms that are clinically promising, what's missing within both the autoimmune and transplant space is the ability to identify antigens that need to be targeted. This workshop will explore applicable techniques that are amenable for identifying novel targets including antigens, auto-antigens and epitopes in the autoimmune and transplant space.

The application of hybrid peptide epitopes will be explored whilst epitope spreading and the role of bystander suppression will also be analyzed.

Workshop Co-Leaders



Stephen Miller
Co-Founder of **Cour Pharmaceuticals**;
Professor of Microbiology-Immunology
Northwestern University Medical School



Simi Ahmed
Director of Research & Lead of the Immune
Therapies Program
JDRF



Martin Roland
Head - Department of Neuroimmunology &
Multiple Sclerosis Research
University Hospital Zurich

Workshop B

1:00pm – 4:00pm

Tolerance Induction in Antigen Specific Immunotherapies: Applications to Transplantation

This interactive workshop will look to explore tolerance induction within transplantation and examine what lessons can be applied to the antigen specific immune tolerance space.

Hear about and discuss:

- Current standards in immune modulation in tissue/organ transplantation – what are the shortcomings and needs of surgeons?
- Tolerance in organ transplantation – current state of the art and science
- Application of ASIT to transplantation – opportunities and challenges

Workshop Leader



Shahrokh Shabahang
Chief Innovation Officer
AdiTx Therapeutics

With insight from:



Waldo Concepcion
Professor of Surgery (Abdominal
Transplantation) & of Pediatrics
(Nephrology)
Stanford University Medical Center



Giles Benichou
Associate Professor of Surgery, **Harvard
Medical School**, Senior Immunologist
Massachusetts General Hospital

Conference Day One

Wednesday February 26, 2020

David Alleva
Executive Director
Akston Biosciences

7.50 Chair's Opening Remarks

An Overview of Progress Towards Achieving Successful Antigen Specific Therapeutics

Emilio Flano
Director & Head
of Immunology
Discovery
Merck & Co

8.00 Antigen-Specific Immunotherapy Approaches for the Treatment of Autoimmune Diseases

- Antigen independent and antigen-specific approaches in immunotherapy
- T cell modulators: approaches for epitope-specific deletion, suppression, or conversion to a regulatory phenotype
- TCR mimetic antibodies: blocking TCR recognition of an HLA:peptide complex and thus T cell activation

Arpita Maiti
Executive Director &
Global Head
Pfizer

8.30 Translating Innovative Science to Therapies that Establish Immune Tolerance – One Pharma's Perspective

- Overview of how to approach immune tolerance as potential curative therapies for autoimmune diseases through internal efforts and collaboration
- Leveraging innovative partnership models to access innovation

Clinical Readouts & Translation: What can we Learn from the Clinic? Implications for Designing Clinical Trials

David Wraith
Director of the
Institute of
Immunology &
Immunotherapy
University of
Birmingham

9.00 Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases

- Review different approaches for induction of antigen-specific immunotherapy
- Report on mechanisms of immunotherapy with antigen processing independent T cell epitopes (apitopes), describing recent clinical trials of the approach for immunotherapy of autoimmune diseases
- Explore the potential for combination approaches to promote antigen-specific immunotherapy

Stephen Miller
Co-Founder of Cour
Pharmaceuticals;
Professor of
Microbiology-
Immunology
Northwestern
University Medical
School

9.30 From Bench to Bedside: Pre-Clinical & Clinical Results of Tolerogenic Therapy of Celiac Disease using Gliadin-Encapsulating PLG Nanoparticles

- Tolerance induction using antigen-encapsulating PLG nanoparticles (Ag-PLG) recapitulates how self-tolerance is induced and maintained in the hematopoietic system
- Ag-PLG uptake by splenic marginal zone and liver APCs confers a tolerogenic phenotype
- Ag-PLG induces the induction of CD4+Foxp3+, CD4+ Tr1, and CD8+CD122+ regulatory T cells



10.00 Speed Networking

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the Antigen-Specific Immune Tolerance field and establish meaningful business relationships to pursue for the rest of the conference.

10.30 Morning Break & Refreshments

Clinical Readouts & Translation: What can we Learn from the Clinic? Implications for Designing Clinical Trials

 Aaron Michels Associate Professor of Pediatrics Medicine, & Immunology, Barbara Davis Center for Diabetes, University of Colorado; Chief Scientific Officer IM Therapeutics	11.00 From Mechanism to Clinical Trial – Blocking Disease-Specific HLA in Type 1 Diabetes • The HLA-DQ8 gene confers significant risk for developing type 1 diabetes and is present in 50-60% of all patients • The HLA-DQ8 molecule is remarkably amenable to binding small molecules within pockets in the peptide-binding groove • A clinically well-established small molecule drug, Methyldopa, blocks DQ8 binding to disease-specific antigens in type 1 diabetes
 Kei Kishimoto Chief Scientific Officer Selecta Biosciences	11.30 Mitigation of Anti-Drug Antibodies with ImmTOR Tolerogenic Nanoparticles • Pre-clinical development of ImmTOR • SEL-212 Phase 2 clinical proof-of-concept with a pegylated uricase enzyme • Application to gene therapy
	12.00 Lunch & Networking

Optimizing the Identification of Novel Targets: Evaluation of Antigen & Epitope Discovery

 Anne De Groot Founder, Chief Executive Officer & Chief Scientific Officer Epivax	1.00 Antigen Discovery for Tolerance Induction (Using Immunoinformatics) • Tolerance induction requires antigen specificity - for some diseases, antigens are unknown • T cell epitopes are critical to both immunogenicity and tolerance in antigen-specific tolerance induction • Immunoinformatics tools can be used to screen antigen targets; their Treg epitope and T effector epitope content can be measured in silicon and validated <i>in vitro</i> and <i>in vivo</i> • Case studies of autoimmune disease antigens that have been discovered and evaluated using Immunoinformatics tools will be discussed
 Martin Roland Head - Department of Neuroimmunology & Multiple Sclerosis Research University Hospital Zurich	1.30 Antigen Discovery as Key Prerequisite for Successful Tolerization & Vaccination Strategies in Autoimmune Diseases, Allergies & Oncology • Challenges of antigen discovery in the autoimmune disease and tumor immunology field • Comparison of antigen discovery strategies • Presentation and discussion of our own approach with several proof-of-principle examples

Tolerance Delivery Systems & Trial Design Optimization

 Shahrokh Shabahang Chief Innovation Officer AdiTxt Therapeutics	2.00 The Importance of Tolerance Delivery Systems in Antigen-Specific Immune Tolerance • Importance of tolerance delivery systems • ADi's design philosophy and approach as a model for tolerance delivery: challenges and possibilities • Translation of ADi from animal models to the clinic
	2.30 Afternoon Break & Refreshments
 Cory Berkland Distinguished Professor, School of Pharmacy Pharmaceutical Chemistry University of Kansas	3.00 A Review of Clinically Tested ASIT Delivery Systems & Implications for Future Design • Explore clinical formulations and delivery of ASIT • Immune mechanisms relating to the delivery and physicochemical properties of ASIT • Design of delivery systems for ASIT to engage particular immune pathways

 Curtis Ruegg President & Chief Executive Officer Parvus Therapeutics, Inc.	3.30 Induction of Antigen-specific TR1 Cells & Therapeutic Outcomes in Autoimmune Models Using Navacim™ Precision Nanomedicines • Direct evidence for induction of antigen-specific type 1 T regulatory cells • The nanoparticle component is more than just a delivery system • Navacim-induced antigen-specific TR1 cells induce therapeutic bystander suppression
 Colin Dayan Professor of Clinical Diabetes & Metabolism Cardiff University School of Medicine	4.00 Novel Approaches to Antigen Delivery & Immune Response Monitoring • Antigen specific immunotherapy with gold nanoparticles • Flow cytometry of lymph nodes in new-onset type 1 diabetes • Single cell analysis of skin blisters and draining lymph nodes following antigen specific immunotherapy
 David Alleva Executive Director Akston Biosciences	4.30 Chair's Closing Remarks
	4.40 Scientific Poster Session The learning and networking continues at the Poster Session, an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new, beneficial relationships. You will have the opportunity to present and review presentations displaying new data for antigen-specific immunotherapies.

Excellent networking and learning opportunity for pharma scientists

Matthew Kennedy, Director, **Merck**

A great opportunity to meet like-minded individuals and discuss the common issues that we all face in drug discovery. Really competent speakers and a great overall atmosphere

Patrick Downey, Director, **UCB**

Conference Day Two

Thursday February 27, 2020

David Alleva Executive Director Akston Biosciences	8.20 Chair's Opening Remarks
The Third Access: Successfully Inducing Tolerance	
Jack Ragheb Senior Medical Fellow for Immunology in Global Patient Safety Eli Lilly & Co.	8.30 Checkpoint Inhibitors: Insights into Immune Tolerance - Review of immune ontogeny and the establishment of immune tolerance - Checkpoint inhibitors and their safety profile - What Checkpoint inhibitors teach us about the maintenance of immune tolerance
Matthias von Herrath Vice President Novo Nordisk	9.00 Exploring the Parameters by which Tolerance Induction is Determined - Antigenic tolerance would lead to less systemic side effects and quasi site specific suppression of autoimmunity - Evaluate the lack of reliable markers to assess successful reduction of antigenic responses in humans - Understanding the rules by which tolerance might be optimally induced and there are many unsubstantiated claims in this research space
Stephan Kontos Founder & Chief Scientific Officer Anokion	9.30 Translational & Clinical Development of Novel, Liver Targeted Immune Tolerance Therapies for Celiac Disease & Multiple Sclerosis - Restoration of normal immune tolerance using antigen mediated immune tolerance approaches - Monitoring of immune tolerance induction via multiple scientific and clinical laboratory methods
9.50 Morning Break & Refreshments	
Giles Benichou Associate Professor of Surgery, Harvard Medical School, Senior Immunologist Massachusetts General Hospital	10.50 Immune Tolerance Induction via Allogeneic Exosomes - Allograft tolerance via MHC chimerism achieved with donor exosomes - Restoration of tolerance in mice with ongoing EAE via mixed hematopoietic chimerism and neural stem cell therapy - Prevention of relapses in mice with EAE using allogeneic exosomes
Garth Ringheim Director Immunology Therapeutic Area Clarivate Analysis	11.20 T Cell Anergy Induction by Pharmacological Agents Partially Restricting T Cell Activation - Inducing antigen tolerance in T cells by modulating select T cell receptor signaling pathways - Functional measures in the lab and the clinic to monitor T cell activation and anergy - Mechanisms regulating T cell anergy and the potential for developing new drug candidates



Andreas Lutterotti
Head of
Experimental
Therapies Research
**University
Hospital Zurich**

11.50 Establish Tolerance in MS with Myelin-Peptide Coupled Red Blood Cells

- Successful development of GMP manufacturing process for peptide coupled cells and clinical implementation
- Clinical safety and immunological proof-of-concept data of phase Ib trial
- Challenges and pitfalls in implementing clinical PoC in phase II development

**Tolerance Induction in Parallel Fields:
What Lessons can be Applied for Autoimmune Diseases**



Lawrence Steinman
Professor of
Neurology,
Neurological
Sciences & Pediatrics
Stanford University

12.50 Antigen Specific Tolerance in Autoimmunity & in Gene Therapy

- Description of the engineered DNA platform for tolerance
- Pre-clinical results in gene therapy of Duchenne's Muscular Dystrophy
- Status of Clinical Trials in Type 1 diabetes, myasthenia gravis and neuromyelitis optica

1.00 Lunch & Networking



Kristina M. Harris
Director, Biomarker
& Discovery
Research
**Immune Tolerance
Network**

2.00 Antigen-Specific T & B Cell Profiles as Therapeutic Targets in Allergy & Autoimmune Disease

- High-dimensional phenotyping identifies distinct antigen-specific T and B cell profiles using peripheral blood from patients with allergy and autoimmune disease
- Deletion, deviation, anergy, and exhaustion are potential tolerogenic outcomes of therapy
- Tracking antigen-specific T and B cells during therapy may be a surrogate for clinical response



Monali Manohar
Life Science
Research Scientist
**Stanford
University School
of Medicine**

2.30 Unraveling the Mechanism of Desensitization & Tolerance through Food Allergen-Specific Oral Immunotherapy

- Novel insights into OIT-induced changes in allergen-specific CD4+ T cells favoring desensitization and tolerance
- The role of anti-IgE adjunct treatment in allergen-specific OIT regimen to facilitate immune changes leading to desensitization
- Pivotal role of non-specific immune cell subsets in shaping allergen-specific immune response during OIT

What Assays do we use & when? Developing Assays for Clinical Trials



Dolly Tyan
Professor; Emerita
of Pathology
**Stanford
University School
of Medicine**

3.00 FlowSpot: A Single Platform Assay with Broad Versatility for Measuring Cellular & Humoral Immune Status, Responsiveness & Memory

- Overview of the assay design
- Profiling and measuring T cell and antigen specific BCR (memory B cell) responses
- Assessing responsiveness to antigenic challenges and immunosuppressive drugs
- Determining transplant compatibility and predicting GVHD



David Alleva
Executive Director
**Akston
Biosciences**

3.30 Assay Development for AKS-107, an Insulin-Fc Biologic Designed to Target Insulin-Specific B Cells in Type 1 Diabetes (T1D)

- Insulin-specific B cells promote T1D pathogenesis by acting as antigen-presenting cells that activate pathogenic effector T cells
- Clinical insulin-specific B cell assays are being developed for patient inclusion and therapeutic response monitoring
- Overcome the funding challenges of bringing a novel T1D immunotherapeutic from research to a first-in-human clinical safety trial to enable optimal positioning for subsequent Phase II proof-of-concept trials via T1D consortia

4.00 Afternoon Refreshments & Networking

Exploring Clinical Opportunities to use Combination Strategies to Successfully Deliver Tolerance Inducing Therapeutics

 Joshua Sestak President & Chief Executive Officer, Founder Orion BioScience	4.30 Considerations for Dual Therapy Approaches in Autoimmune Disease • Where the need for dual therapy is greatest • The role of safety in pursuing multiple therapeutic approaches • How to best leverage safety and efficacy in dual therapy
 Giorgio Raimondi Associate Scientific Director for Transplant Immunology John Hopkins School of Medicine	5.00 Novel Applications of Localized Delivery of Combination Strategies for Modulation of Allo- & Auto-Reactivity • A novel rationale for immunomodulation via combination strategy • The use of “injectable hydrogels” for localized modulation of alloreactivity • The use of “lipid nanoparticles” for orally-based modulation of autoreactivity
 Amy Rosenberg Director - Therapeutic Proteins & CDER FDA	5.30 Regulatory Perspective on Combination Therapies • Details to be confirmed


6.00 Panel Discussion: “Bridging the Valley of Death: Non-Profit Organizations as Enablers of Novel Commercial T1D Therapeutics from Research to Phase II”

- Explore what role non-profit organizations can play in addressing the key funding acquisition problems of pre-clinical and clinical development
- From concept to action: A non-profit funding case study
- Evaluating the scope of current non-profit funding programs and where best to place resources along the development stage

Moderator:



Panelists:



6.30 Chair's Closing Remarks

■ ■ This meeting is an ideal opportunity to gain insight into new tolerance strategies and obtain an overview of the existing field ■ ■

Jack Ragheb Senior Medical Fellow for Immunology- Global Patient Safety, **Eli Lilly**

Become a Partner



Innovation Partner

Anokion is focused on improving the treatment and outcomes of autoimmune disease. Our proprietary antigen-specific immune tolerance technology is designed to be both more effective and specific than the current standard of care.

Our therapeutically engineered proteins specifically target the autoreactive cells for removal, while leaving the healthy areas of the immune system untouched. Our antigen-specific approach can be translated to virtually any protein with the potential for widespread clinical use in antigen-mediated autoimmune disease.

Founded in Switzerland and based on innovation from the EPFL Life Sciences, Anokion is led by a diverse team of entrepreneurial scientists and experienced industry professionals, striving to transform treatment for autoimmune patients around the world.

www.anokion.com



Event Partner

Orion BioScience Inc. is a pre-clinical stage biotechnology company focused on developing our "Soluble Antigen Array" (or SAgA) technology to intercept and prevent the onset of autoimmune diseases in at risk and early stage patients. Our research into treating multiple sclerosis, neuromyelitis optica, and type-1 diabetes has shown that Orion can develop disease specific immunotherapeutics that can re-tolerize and restore the healthy immune state. The Orion team leverages extensive development experience, and strong clinical relationships, to rapidly progress first-in-class, blockbuster treatments for NMO and T1D into the clinic.

www.orionbioscience.com

Reasons to Partner with us



Raise Brand Awareness

Take advantage of pre- and post conference exposure to the community of autoimmune, allergy and transplantation KOL's and drive an increase in market share through unique branding formats.



Generate Commercial Collaborations

Make sure your hottest prospects are in the room and part of the discussion by having a wish-list of your choice contacted in advance of the event.



Position Yourself as an Industry Expert

Define your position as an industry thought leader by placing yourself at the forefront of the only meeting dedicated to tackling the challenges behind antigen specific immune tolerance.



Meet and Network with Industry Pioneers

Maximize prospective client interaction with speed networking breaks, 1-2-1 meetings, informal networking receptions and more.

Get involved



Mitchel Davis

Commercial Director

Tel: 0203 8540 607

Email: Mitchel.Davis@hansonwade.com

Ready to Register? 3 Easy Ways to Book

Web: www.as-immunetolerance.com/take-part/register

Tel: +1 617 455 4188

Email: register@hansonwade.com

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

- 1 Explore cross learning opportunities and benchmark your drug development process with parallel fields also tackling immune tolerance and accelerate translation into the clinic
- 2 Join the debate and work towards defining tolerance induction and the parameters by which tolerance itself can be measured
- 3 Review some of the first clinical trial readouts for antigen specific immune tolerance therapeutics and explore the fundamental mechanisms that lie behind successful and unsuccessful clinical trial design and delivery

Secure Your Place

Industry Pricing	Register and Pay by Friday October 11 2019	Standard Price
Conference + 2 Workshops	\$2,999	\$3799
Conference + 1 Workshop	\$2,599	\$3399
Conference Only	\$2099	\$2899
Workshop Day Only	\$998	

Academic/Not for Profit Pricing	Register and Pay by Friday October 11 2019	Standard Price
Conference + 2 Workshops	\$2,099	\$2699
Conference + 1 Workshop	\$1,799	\$2299
Conference Only	\$1,399	\$1899
Workshop Day Only	\$798	



Venue

The Colonnade Hotel

120 Huntington Avenue, Boston, MA 02116, (617), 424-7000

For further information or assistance, please visit
www.colonnadehotel.com or call +1-800-962-3030

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH